This is great news. The BiOasis train is really picking up steam. It won't be long now until clinical manufacturing begins for xB3-001 and also hopefully we hear something about the non-human primate (NHP) validation of xB3-001. NHP studies before or after clinical production of xB3-001? Choo-choo!

From the most recent MD&A:

"To gain a deep understanding of these programs the Company will utilize 3D whole brain imaging to assess target engagement and pharmacodynamics biomarkers (e.g., glucose utilization, neurochemical changes, etc.) and to increase the probability of selecting the optimal doses for all of our therapeutic candidates."

For xB3-001/Brain Metastases: "In Q1 clinical manufacturing will begin in preparation for clinical studies."